[PDF][PDF] Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease

KJ Mayne, N Staplin, DF Keane… - Journal of the …, 2024 - journals.lww.com
BACKGROUND: Chronic kidney disease (CKD) is associated with fluid excess which can be
estimated by bioimpedance spectroscopy. We aimed to assess effects of sodium glucose co-
transporter 2 inhibition on bioimpedance-derived “Fluid Overload” and adiposity in a CKD
population. METHODS: EMPA-KIDNEY was a double-blind placebo-controlled trial of
empagliflozin 10 mg once daily in patients with CKD at risk of progression. In a substudy,
bioimpedance measurements were added to the main trial procedures at randomization and …
以上显示的是最相近的搜索结果。 查看全部搜索结果